Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:15 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532998 | NSE: LOTUSEYE

Lotus Eye Hospital & Institute Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹94.77Fairly Valued by 7.09%vs CMP ₹102.00

P/E (326.0) × ROE (1.2%) × BV (₹29.20) × DY (2.00%)

₹24.50Overvalued by 75.98%vs CMP ₹102.00
MoS: -316.3% (Negative)Confidence: 70/100 (High)Models: All 10: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹69.8021%Over (-31.6%)
Graham NumberEarnings₹14.2715%Over (-86%)
Earnings PowerEarnings₹8.6910%Over (-91.5%)
DCFCash Flow₹0.7713%Over (-99.2%)
Net Asset ValueAssets₹29.177%Over (-71.4%)
EV/EBITDAEnterprise₹29.308%Over (-71.3%)
Dividend DiscountDividends₹5.108%Over (-95%)
Earnings YieldEarnings₹3.107%Over (-97%)
ROCE CapitalReturns₹9.687%Over (-90.5%)
Revenue MultipleRevenue₹23.845%Over (-76.6%)
Consensus (10 models)₹24.50100%Overvalued
Key Drivers: EPS CAGR -26.3% drags value — could be higher if earnings stabilize. | P/E of 326 makes PE-ROE unreliable — asset/earnings models are better benchmarks.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -26.3%

*Investments are subject to market risks

Investment Snapshot

56
Lotus Eye Hospital & Institute Ltd scores 56/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health62/100 · Moderate
ROCE 3.0% WeakROE 1.2% WeakD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.01% (6mo) Slight increasePromoter holding at 40.7% Stable
Earnings Quality50/100 · Moderate
OPM contracting (16% → 10%) DecliningWorking capital: 0 days (improving) Efficient
Quarterly Momentum80/100 · Strong
Revenue (4Q): +5% YoY GrowingProfit (4Q): +30% YoY Strong
Industry Rank20/100 · Weak
P/E 326.0 vs industry 103.6 Premium to peersROCE 3.0% vs industry 10.6% Below peersROE 1.2% vs industry 10.7% Below peers3Y sales CAGR: 8% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Lotus Eye Hospital & Institute Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
70/100
High
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 326.0 vs Ind 103.6 | ROCE 3.0% | ROE 1.2% | CFO/NP N/A
Balance Sheet Stress
20/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.00x | IntCov 0.0x | Current 2.34x | Borrow/Reserve 0.12x
Cash Flow Reliability
29/100
Weak
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹1 Cr | CFO/NP N/A
Ownership Accumulation
+50
Accumulation
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII +0.01 pp | DII 0.00 pp | Prom +0.03 pp
Business Momentum
0
Early weakness
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales +3.9% | Q NP -316.7% | Q OPM -1.0 pp
Derived FieldValueHow it is derived
Valuation Gap %-76.0%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves0.12xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII Change+0.01 ppLatest FII% minus previous FII%
DII Change0.00 ppLatest DII% minus previous DII%
Promoter Change+0.03 ppLatest promoter% minus previous promoter%
Shareholder Count Change-537Latest shareholder count minus previous count
Quarterly Sales Change+3.9%Latest quarter sales vs previous quarter sales
Quarterly Profit Change-316.7%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change-1.0 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:15 am

Market Cap 212 Cr.
Current Price 102
Intrinsic Value₹24.50
High / Low 148/62.0
Stock P/E326
Book Value 29.2
Dividend Yield0.00 %
ROCE2.99 %
ROE1.22 %
Face Value 10.0
PEG Ratio-12.37

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Lotus Eye Hospital & Institute Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lotus Eye Hospital & Institute Ltd 212 Cr. 102 148/62.0326 29.20.00 %2.99 %1.22 % 10.0
Asarfi Hospital Ltd 348 Cr. 177 221/72.920.7 45.20.00 %15.8 %14.1 % 10.0
Narayana Hrudayalaya Ltd 33,417 Cr. 1,635 2,372/1,38040.5 1990.28 %20.8 %24.2 % 10.0
Dr Lalchandani Labs Ltd 12.8 Cr. 14.8 21.2/8.1527.3 11.70.00 %2.81 %3.08 % 10.0
Industry Average11,325.67 Cr482.20103.6371.280.07%10.60%10.65%10.00

All Competitor Stocks of Lotus Eye Hospital & Institute Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 12.1411.1712.5712.7312.0310.8812.8912.9112.2511.5113.5213.0413.55
Expenses 10.039.7810.1810.9210.4510.1211.2311.7611.4611.6812.0412.2712.89
Operating Profit 2.111.392.391.811.580.761.661.150.79-0.171.480.770.66
OPM % 17.38%12.44%19.01%14.22%13.13%6.99%12.88%8.91%6.45%-1.48%10.95%5.90%4.87%
Other Income 0.320.360.290.280.340.400.310.270.220.520.190.270.24
Interest 0.020.020.020.010.040.030.060.080.130.090.120.120.29
Depreciation 0.770.780.730.890.981.121.061.231.31-0.580.820.850.98
Profit before tax 1.640.951.931.190.900.010.850.11-0.430.840.730.07-0.37
Tax % 29.88%31.58%27.98%28.57%26.67%-200.00%28.24%9.09%-44.19%70.24%24.66%-71.43%-29.73%
Net Profit 1.160.651.380.850.660.020.620.10-0.240.250.540.12-0.26
EPS in Rs 0.560.310.660.410.320.010.300.05-0.120.120.260.06-0.13

Last Updated: March 4, 2026, 1:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 9:16 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 28.6929.9031.1333.9638.0238.4340.5532.3538.9047.0348.2049.5551.62
Expenses 25.4027.7227.1430.6333.6835.2136.5728.7332.9839.3541.5745.9948.88
Operating Profit 3.292.183.993.334.343.223.983.625.927.686.633.562.74
OPM % 11.47%7.29%12.82%9.81%11.42%8.38%9.82%11.19%15.22%16.33%13.76%7.18%5.31%
Other Income 0.390.460.580.680.910.680.210.840.881.151.311.311.22
Interest 0.040.100.160.150.180.210.240.140.210.200.200.480.62
Depreciation 3.544.764.443.443.373.062.502.332.502.983.733.012.07
Profit before tax 0.10-2.22-0.030.421.700.631.451.994.095.654.011.381.27
Tax % 60.00%-10.81%-400.00%-7.14%-2.35%-12.70%26.90%21.11%27.14%27.79%27.43%46.38%
Net Profit 0.04-1.980.100.441.750.711.061.572.984.082.910.740.65
EPS in Rs 0.02-0.950.050.210.840.340.510.751.431.961.400.360.31
Dividend Payout % 0.00%0.00%0.00%236.36%59.43%0.00%0.00%66.24%34.90%25.49%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-5050.00%105.05%340.00%297.73%-59.43%49.30%48.11%89.81%36.91%-28.68%-74.57%
Change in YoY Net Profit Growth (%)0.00%5155.05%234.95%-42.27%-357.16%108.72%-1.18%41.70%-52.90%-65.59%-45.89%

Lotus Eye Hospital & Institute Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:5%
5 Years:4%
3 Years:8%
TTM:3%
Compounded Profit Growth
10 Years:9%
5 Years:-13%
3 Years:-38%
TTM:-70%
Stock Price CAGR
10 Years:26%
5 Years:33%
3 Years:25%
1 Year:61%
Return on Equity
10 Years:3%
5 Years:4%
3 Years:4%
Last Year:1%

Last Updated: September 5, 2025, 9:50 am

Balance Sheet

Last Updated: December 4, 2025, 1:34 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 20.8020.8020.8020.8020.8020.8020.8020.8020.8020.8020.8020.8020.80
Reserves 30.5728.5928.6929.2629.8429.3230.4631.9033.8136.7838.6139.2039.82
Borrowings 0.180.830.660.480.290.220.320.401.240.671.113.434.80
Other Liabilities 7.016.204.684.407.286.186.536.125.754.936.116.146.09
Total Liabilities 58.5656.4254.8354.9458.2156.5258.1159.2261.6063.1866.6369.5771.51
Fixed Assets 46.9447.0443.5741.3242.5244.1442.6740.5444.0744.1848.6554.0755.17
CWIP 0.360.270.420.650.290.290.000.000.000.000.080.000.06
Investments 0.000.000.000.000.000.000.000.000.000.000.000.000.00
Other Assets 11.269.1110.8412.9715.4012.0915.4418.6817.5319.0017.9015.5016.28
Total Assets 58.5656.4254.8354.9458.2156.5258.1159.2261.6063.1866.6369.5771.51

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 4.412.373.382.975.784.204.972.734.414.395.682.70
Cash from Investing Activity + -5.05-4.65-0.85-1.06-3.86-4.01-0.680.49-3.94-2.19-4.63-6.13
Cash from Financing Activity + -0.771.87-0.58-0.25-1.51-1.410.13-0.32-1.58-1.71-3.40-1.60
Net Cash Flow -1.41-0.401.961.660.41-1.224.422.90-1.100.49-2.35-5.03
Free Cash Flow -0.91-2.382.281.551.58-0.493.542.61-0.251.300.10-2.09
CFO/OP 135%109%85%92%142%134%132%84%89%76%101%94%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow3.111.353.332.854.053.003.663.224.687.015.520.13

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 4.964.275.987.3110.947.225.948.355.829.089.549.72
Inventory Days 166.70121.54113.2560.2279.23128.20124.42138.82150.03153.60170.30193.62
Days Payable 130.52125.08105.5187.32129.95167.37170.41220.72231.21173.42183.56169.86
Cash Conversion Cycle 41.140.7313.72-19.79-39.78-31.95-40.05-73.54-75.37-10.74-3.7233.48
Working Capital Days -13.10-19.90-8.56-8.92-26.02-15.39-21.33-23.92-16.338.614.850.00
ROCE %0.27%-4.23%0.24%1.19%3.63%1.66%4.67%3.92%7.91%10.25%7.07%2.99%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 58.17%58.44%57.58%56.58%41.40%40.24%40.03%40.14%40.22%40.39%40.63%40.66%
FIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.00%0.01%
DIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.04%0.04%0.02%0.02%0.02%
Public 41.83%41.56%42.43%43.42%58.60%59.76%59.97%59.82%59.73%59.57%59.33%59.31%
No. of Shareholders 7,3457,4257,6608,31412,50211,75912,51411,73411,50811,12110,77710,240

Shareholding Pattern Chart

No. of Shareholders

Lotus Eye Hospital & Institute Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 0.361.401.961.440.75
Diluted EPS (Rs.) 0.361.401.961.440.75
Cash EPS (Rs.) 1.803.193.392.641.87
Book Value[Excl.RevalReserv]/Share (Rs.) 28.8528.5727.6926.2625.34
Book Value[Incl.RevalReserv]/Share (Rs.) 28.8528.5727.6926.2625.34
Dividend / Share (Rs.) 0.000.500.500.500.50
Revenue From Operations / Share (Rs.) 23.8323.1822.6218.7115.56
PBDIT / Share (Rs.) 2.283.774.203.242.07
PBIT / Share (Rs.) 0.831.972.772.030.95
PBT / Share (Rs.) 0.661.932.721.970.95
Net Profit / Share (Rs.) 0.351.401.961.440.75
PBDIT Margin (%) 9.5516.2418.5617.3013.30
PBIT Margin (%) 3.488.5112.2210.876.10
PBT Margin (%) 2.788.3212.0110.526.15
Net Profit Margin (%) 1.496.048.667.674.84
Return on Networth / Equity (%) 1.234.907.085.462.97
Return on Capital Employeed (%) 2.786.799.917.573.69
Return On Assets (%) 1.064.376.454.842.64
Asset Turnover Ratio (%) 0.720.740.750.640.55
Current Ratio (X) 1.562.252.832.242.34
Quick Ratio (X) 1.041.742.301.842.03
Inventory Turnover Ratio (X) 14.082.813.283.192.61
Dividend Payout Ratio (NP) (%) 0.0035.670.000.000.00
Dividend Payout Ratio (CP) (%) 0.0015.650.000.000.00
Earning Retention Ratio (%) 0.0064.330.000.000.00
Cash Earning Retention Ratio (%) 0.0084.350.000.000.00
Interest Coverage Ratio (X) 13.3480.4289.4752.5666.35
Interest Coverage Ratio (Post Tax) (X) 3.0530.8642.8024.3823.91
Enterprise Value (Cr.) 141.22110.46112.37102.1077.22
EV / Net Operating Revenue (X) 2.852.292.392.622.39
EV / EBITDA (X) 29.8314.1012.8715.1717.93
MarketCap / Net Operating Revenue (X) 2.932.442.572.852.69
Retention Ratios (%) 0.0064.320.000.000.00
Price / BV (X) 2.421.982.102.031.65
Price / Net Operating Revenue (X) 2.932.442.572.852.69
EarningsYield 0.010.020.030.020.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Lotus Eye Hospital and Institute Ltd. is a Public Limited Listed company incorporated on 14/03/1997 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L85110TZ1997PLC007783 and registration number is 007783. Currently company belongs to the Industry of Hospitals & Medical Services. Company's Total Operating Revenue is Rs. 49.56 Cr. and Equity Capital is Rs. 20.80 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Hospitals & Medical ServicesS.F No.770/12, Avinashi Road, Coimbatore Tamil Nadu 641014Contact not found
Management
NamePosition Held
Dr. Kavetha SundaramoorthyChairman
Ms. Sangeetha SundaramoorthyManaging Director
Dr. K S RamalingamWholeTime Director & CEO
Mr. Karthik VeeramaniDirector
CA. Perumalsamy MahendranDirector
Dr. S NatesanDirector

FAQ

What is the intrinsic value of Lotus Eye Hospital & Institute Ltd and is it undervalued?

As of 05 April 2026, Lotus Eye Hospital & Institute Ltd's intrinsic value is ₹24.50, which is 75.98% lower than the current market price of ₹102.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (1.22 %), book value (₹29.2), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Lotus Eye Hospital & Institute Ltd?

Lotus Eye Hospital & Institute Ltd is trading at ₹102.00 as of 05 April 2026, with a FY2026-2027 high of ₹148 and low of ₹62.0. The stock is currently in the middle of its 52-week range. Market cap stands at ₹212 Cr..

How does Lotus Eye Hospital & Institute Ltd's P/E ratio compare to its industry?

Lotus Eye Hospital & Institute Ltd has a P/E ratio of 326, which is above the industry average of 103.63. This significantly elevated P/E suggests the market expects strong future growth, or the stock may be overpriced relative to current earnings.

Is Lotus Eye Hospital & Institute Ltd financially healthy?

Key indicators for Lotus Eye Hospital & Institute Ltd: ROCE of 2.99 % is on the lower side compared to the industry average of 10.60%; ROE of 1.22 % is below ideal levels (industry average: 10.65%). Dividend yield is 0.00 %.

Is Lotus Eye Hospital & Institute Ltd profitable and how is the profit trend?

Lotus Eye Hospital & Institute Ltd reported a net profit of ₹1 Cr in Mar 2025 on revenue of ₹50 Cr. Compared to ₹3 Cr in Mar 2022, the net profit shows a declining trend.

Does Lotus Eye Hospital & Institute Ltd pay dividends?

Lotus Eye Hospital & Institute Ltd has a dividend yield of 0.00 % at the current price of ₹102.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Lotus Eye Hospital & Institute Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports